🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation

Published 18/04/2024, 19:29
© Reuters.  To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
TSLA
-
ARKK
-
ALLO
-
ARKX
-
COIN
-
HOOD
-

Benzinga - by Johnny Rice, Benzinga Staff Writer.

Investing in the technologies of tomorrow can be a lucrative investment strategy. If investors can discern trends as they develop, they can stay ahead of the curve and reap the rewards. This is what made Cathie Wood and her firm ARK Invest famous. Her funds invest in companies she "expect[s] to be the leaders, enablers, and beneficiaries of disruptive innovation."

Wood's big bets have won her a lot of fans, but it hasn't always been a smooth ride. Investing in the cutting-edge means investing in what is largely unproven, and this strategy carries significant risk. The ARK Innovation ETF (NYSE:ARKK), for instance, is down close to 15% this year, largely due to her continued faith in Tesla (NASDAQ:TSLA) whose stock has been hammered recently.

However, with risk comes reward. If a fund can smartly predict the trends of tomorrow, significant upside exists.

MOON Direxion is an award-winning ETF issuer best known for its innovative leveraged and inverse single-stock funds. The company also provides its Direxion Moonshot Innovators ETF (NYSE:MOON) with "exposure to the 50 most innovative U.S. companies at the forefront of changing our lives today, and tomorrow, by identifying the companies both pursuing innovation and having the potential to disrupt existing technologies and/or industries."

The fund tracks the performance of the S&P Kensho Moonshots Index and carries an expense ratio of .65%. The fund currently has assets under management of $21.4 million.

Top Holdings

  • AVIDITY BIOSCIENCES INC (NASDAQ:RNA) – 7.31% of the fund.
  • RNA is a biotechnology company focused on developing RNA-based therapies.

  • 4D MOLECULAR THERAPEUTICS IN (NASDAQ:FDMT) – 4.37% of the fund.
  • FDMT is a clinical-stage biopharma company developing "genetic medicine." The company has a proprietary discovery platform called Therapeutic Vector Evolution.

  • COINBASE GLOBAL INC -CLASS A (NASDAQ:COIN) – 3.91% of the fund.
  • COIN is the most popular cryptocurrency exchange in the United States. It is also another favorite of Cathie Wood and the second largest holding currently in ARKK.

  • ROBINHOOD MARKETS INC – A (NASDAQ:HOOD)
  • HOOD is a technology company best known for its no-fee trading platform.

  • ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) – 3.38% of the fund.
  • ALLO is another clinical-stage biopharma company. It develops "investigational allogeneic chimeric antigen receptor T cell (AlloCAR T™)" therapies to fight cancer.

    Featured photo by Pedro Lastra on Unsplash.

    © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    Read the original article on Benzinga

    Latest comments

    Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
    Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
    Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
    It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
    Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
    © 2007-2024 - Fusion Media Limited. All Rights Reserved.